CN1543504A - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN1543504A
CN1543504A CNA028093240A CN02809324A CN1543504A CN 1543504 A CN1543504 A CN 1543504A CN A028093240 A CNA028093240 A CN A028093240A CN 02809324 A CN02809324 A CN 02809324A CN 1543504 A CN1543504 A CN 1543504A
Authority
CN
China
Prior art keywords
protein
mouse
human
cil
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028093240A
Other languages
English (en)
Chinese (zh)
Inventor
C
C·阿斯曼
ά
J·S·克罗维
J·H·埃利斯
·
A·P·路易斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1543504A publication Critical patent/CN1543504A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028093240A 2001-03-03 2002-03-01 疫苗 Pending CN1543504A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105360.2 2001-03-03
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens

Publications (1)

Publication Number Publication Date
CN1543504A true CN1543504A (zh) 2004-11-03

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028093240A Pending CN1543504A (zh) 2001-03-03 2002-03-01 疫苗

Country Status (18)

Country Link
US (3) US20050260216A1 (https=)
EP (1) EP1368477A1 (https=)
JP (1) JP4238031B2 (https=)
KR (1) KR20030081490A (https=)
CN (1) CN1543504A (https=)
AU (1) AU2002233560B2 (https=)
BR (1) BR0207819A (https=)
CA (1) CA2439628A1 (https=)
CZ (1) CZ20032373A3 (https=)
GB (1) GB0105360D0 (https=)
HU (1) HUP0303372A3 (https=)
IL (1) IL157498A0 (https=)
MX (1) MXPA03007915A (https=)
NO (1) NO20033882L (https=)
NZ (1) NZ527873A (https=)
PL (1) PL365066A1 (https=)
WO (1) WO2002070711A1 (https=)
ZA (1) ZA200306647B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997395B (zh) * 2004-06-11 2012-08-29 独立行政法人理化学研究所 含有包含在脂质体中的调节性细胞配体的药物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP2006503017A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AU2003263150A1 (en) * 2002-09-12 2004-04-30 Pharmexa A/S Immunization against autologous ghrelin
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
ATE552860T1 (de) * 2003-01-31 2012-04-15 Celldex Res Corp Antikörper-vakzine-konjugate und ihre verwendungen
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
WO2008147956A2 (en) * 2007-05-25 2008-12-04 Centocor, Inc. Toll-like receptor 3 modulators and uses thereof
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP2024504194A (ja) * 2021-01-29 2024-01-30 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 自己寛容を破壊するためのワクチン組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
EP0815136B1 (en) * 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
JP2002506618A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 腫瘍自己抗原に対する免疫誘導
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
EP1263785A2 (en) * 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997395B (zh) * 2004-06-11 2012-08-29 独立行政法人理化学研究所 含有包含在脂质体中的调节性细胞配体的药物

Also Published As

Publication number Publication date
NO20033882L (no) 2003-10-31
KR20030081490A (ko) 2003-10-17
BR0207819A (pt) 2004-03-02
US20030194391A1 (en) 2003-10-16
US20050186209A1 (en) 2005-08-25
CZ20032373A3 (cs) 2004-01-14
ZA200306647B (en) 2004-11-26
MXPA03007915A (es) 2003-12-04
GB0105360D0 (en) 2001-04-18
NZ527873A (en) 2005-12-23
JP4238031B2 (ja) 2009-03-11
HUP0303372A2 (hu) 2004-01-28
JP2005502314A (ja) 2005-01-27
WO2002070711A1 (en) 2002-09-12
NO20033882D0 (no) 2003-09-02
AU2002233560B2 (en) 2006-09-07
CA2439628A1 (en) 2002-09-12
PL365066A1 (en) 2004-12-27
EP1368477A1 (en) 2003-12-10
HUP0303372A3 (en) 2008-06-30
IL157498A0 (en) 2004-03-28
US20050260216A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
CN1543504A (zh) 疫苗
CN1178955C (zh) 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
CN1308037C (zh) 增强蛋白和肽抗原免疫原性的Fc融合蛋白
CN1384757A (zh) 下调gdf－8活性的方法
CN101076352A (zh) Il－15抗原阵列及其用途
CN1318105A (zh) 负调节Osteoprotegerin配体活性的方法
CN1960752A (zh) 非人类tnf－肽的载体偶联物的医药用途
CN1194000A (zh) 增强保护性免疫应答的方法
AU2002233560A1 (en) Vaccine
CN1558775A (zh) 用于治疗变应性嗜酸细胞性疾病的展示il-5、il-3或嗜酸细胞活化趋化因子的抗原阵列
CN1355846A (zh) 用于下调节白细胞介素5活性的方法
CN1741818A (zh) 线虫多肽佐剂
CN1714153A (zh) 重组蛋白质变异体
CN1705492A (zh) 用于诱发抗过敏原保护性免疫应答的重组核酸
CN1649898A (zh) 新型肽及其的治疗中的应用
CN1230223A (zh) 高亲和性白细胞介素－4突变蛋白质
CN1158387C (zh) 编码l.infantum的四种蛋白质的抗原决定簇的嵌合基因
CN101031647A (zh) 在大肠杆菌中制备猪丹毒杆菌表面保护性抗原变体的方法
CN1620466A (zh) 胱氨酸结折迭蛋白质
CN1639569A (zh) 诱导免疫应答的方法和组合物
CN1960744A (zh) 肽IL1β和TNFα以及应用其治疗的方法
CN1190437A (zh) 骨刺激因子
CN1867588A (zh) 包含c4bp核心蛋白质和单体抗原的产品及其用途
CN1809381A (zh) 具有稀有二硫化物结构的hiv－1包膜糖蛋白
CN1760205A (zh) 睫状神经营养因子(cntf)突变体及其生产方法和其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication